

12

PATENT APPLICATION
ATTORNEY DOCKET NO.: 01017/36917A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Medlock, *et al.*

Serial No: 09/810,927

Filed: March 16, 2001

For: IL-17 RECEPTOR LIKE
MOLECULES AND USES
THEREOF

Group Art Unit: 1645

Examiner: TBD



) I hereby certify that this paper is being
) deposited with the United States Postal Service
) as First Class mail, postage prepaid, in an
) envelope addressed to: Commissioner for
) Patents, Washington, D.C. 20231 on March 13,
) 2002.

Thomas A. Cawley, Jr.

Thomas A. Cawley, Jr., Ph.D.
Registration No: 40,944
Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached Form PTO-1449 and copies of the documents cited therein are hereby submitted by the applicants for consideration in connection with the above-identified patent application.

This information disclosure statement is not intended to be admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

In accordance with 37 C.F.R. § 1.97(e), each item of information contained in the information disclosure statement was first cited in the International Search Report from the European Patent Office (International Search Authority) in a counterpart PCT application less than three months prior to filing of this information disclosure statement.

Further this statement and the Form PTO-1449 are submitted before receipt of a first office action in the above-identified patent application. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). If it is determined, however, that any appropriate fee is due, please charge Deposit Account 13-2855. A duplicate of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By



Thomas A. Cawley Jr., Ph.D.

Registration No. 40,944

Attorney for Applicants

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300

March 13, 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01017/36917A

Serial No.

09/810.927

Applicant

Medlock *et al.*

Filing Date

March 16, 2001

Group

1645

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B3	WO 99/14240	3/25/99	PCT	C07K			
	B4	WO 99/35263	7/15/99	PCT	C12N			
	B5	WO 00/55204	9/21/00	PCT	C07K			
	B6	WO 00/60080	10/12/00	PCT	C12N			
	B7	WO 01/57202	8/9/01	PCT	C12N			
	B8	WO 01/59120	8/16/01	PCT	C12N			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C3	Tian, <i>et al.</i> , "Evi27 Encodes a Novel Membrane Protein with Homology to the IL-17 Receptor," <i>Oncogene</i> 19:2098-2109 (2000).
	C4	Yao, <i>et al.</i> , "Molecular Characterization of the Human Interleukin (IL)-17 Receptor," <i>Cytokine</i> 9:794-800 (1997).
	C5	International Search Report. European Patent Office. Mailed February 14, 2002.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.